BACKGROUND: Women-specific factors exist that increases vulnerability to drug-related harms from injection drug use, including blood-borne viruses (BBVs), but gender-based differences in BBV prevalence have not been systematically examined. METHODS: We conducted meta-analyses to estimate country, regional, and global prevalence of serologically confirmed human immunodeficiency virus (HIV), hepatitis C virus (HCV; based on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surface antigen) in people who inject drugs (PWID), by gender. Gender-based differences in the BBV prevalence (calculated as the risk among women relative to the risk among men) were regressed on country-level prevalence and inequality measures (Gender inequality index, Human development index, Gini coefficient, and high, low or middle income of the country). RESULTS: Gender-based differences varied by countries and regions. HIV prevalence was higher among women than men in sub-Saharan Africa (relative risk [RR], 2.8; 95% confidence interval [CI], 1.8-4.4) and South Asia (RR, 1.7; 95% CI, 1.1-2.7); anti-HCV was lower among women in the Middle East and North Africa (RR, 0.6; 95% CI, .5-.7) and East and Southeast Asia (RR, 0.8; 95% CI, .7-.9). Gender-based differences varied with country-levels of the BBV prevalence in the general population, human development, and income distribution. CONCLUSION: HIV was more prevalent in women who inject drugs as compared to their male counterparts in some countries, but there is variation between and within regions. In countries where women are at higher risks, there is a need to develop gender-sensitive harm-reduction services for the particularly marginalized population of women who inject drugs.
BACKGROUND:Women-specific factors exist that increases vulnerability to drug-related harms from injection drug use, including blood-borne viruses (BBVs), but gender-based differences in BBV prevalence have not been systematically examined. METHODS: We conducted meta-analyses to estimate country, regional, and global prevalence of serologically confirmed humanimmunodeficiency virus (HIV), hepatitis C virus (HCV; based on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surface antigen) in people who inject drugs (PWID), by gender. Gender-based differences in the BBV prevalence (calculated as the risk among women relative to the risk among men) were regressed on country-level prevalence and inequality measures (Gender inequality index, Human development index, Gini coefficient, and high, low or middle income of the country). RESULTS: Gender-based differences varied by countries and regions. HIV prevalence was higher among women than men in sub-Saharan Africa (relative risk [RR], 2.8; 95% confidence interval [CI], 1.8-4.4) and South Asia (RR, 1.7; 95% CI, 1.1-2.7); anti-HCV was lower among women in the Middle East and North Africa (RR, 0.6; 95% CI, .5-.7) and East and Southeast Asia (RR, 0.8; 95% CI, .7-.9). Gender-based differences varied with country-levels of the BBV prevalence in the general population, human development, and income distribution. CONCLUSION:HIV was more prevalent in women who inject drugs as compared to their male counterparts in some countries, but there is variation between and within regions. In countries where women are at higher risks, there is a need to develop gender-sensitive harm-reduction services for the particularly marginalized population of women who inject drugs.
Authors: Don C Des Jarlais; Jonathan P Feelemyer; Shilpa N Modi; Kamyar Arasteh; Holly Hagan Journal: Drug Alcohol Depend Date: 2012-01-17 Impact factor: 4.492
Authors: Kate Shannon; Anna-Louise Crago; Stefan D Baral; Linda-Gail Bekker; Deanna Kerrigan; Michele R Decker; Tonia Poteat; Andrea L Wirtz; Brian Weir; Marie-Claude Boily; Jenny Butler; Steffanie A Strathdee; Chris Beyrer Journal: Lancet Date: 2018-07-20 Impact factor: 79.321
Authors: Kora DeBeck; Tessa Cheng; Julio S Montaner; Chris Beyrer; Richard Elliott; Susan Sherman; Evan Wood; Stefan Baral Journal: Lancet HIV Date: 2017-05-14 Impact factor: 12.767
Authors: Divya Balaji; Linda B Mlunde; Olivia C Tran; Barrot Lambdin; Jessie Mbwambo; Cassian Nyandindi; Eva Matiko; Michael Copenhaver; R Douglas Bruce Journal: AIDS Behav Date: 2017-07
Authors: Sean T Allen; Suzanne M Grieb; Jennifer L Glick; Rebecca Hamilton White; Tyler Puryear; Katherine C Smith; Brian W Weir; Susan G Sherman Journal: Ann Med Date: 2022-12 Impact factor: 4.709
Authors: Stephanie M Matt; Emily A Nickoloff-Bybel; Yi Rong; Kaitlyn Runner; Hannah Johnson; Margaret H O'Connor; Elias K Haddad; Peter J Gaskill Journal: Front Immunol Date: 2021-05-19 Impact factor: 7.561
Authors: Semvua B Kilonzo; Daniel W Gunda; David C Majinge; Hyasinta Jaka; Paulina M Manyiri; Fredrick Kalokola; Grahame Mtui; Elichilia R Shao; Fatma A Bakshi; Alex Stephano Journal: BMC Infect Dis Date: 2021-07-21 Impact factor: 3.090
Authors: Betsy C Sambai; Hanley Kingston; Aliza Monroe-Wise; Loice Mbogo; Emily Juma; Natasha Ludwig-Barron; Brandon L Guthrie; David Bukusi; Bhavna H Chohan; John Scott; Rose Bosire; Matthew Dunbar; Paul Macharia; Sarah Masyuko; William Sinkele; Joshua T Herbeck; Carey Farquhar Journal: BMC Infect Dis Date: 2022-01-21 Impact factor: 3.090